Celltrion Launches Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis in Canada
Shots:
- Celltrion launches the world's first SC formulation of infliximab (120mg- q2w- fd- as a pre-filled pen (auto-injector) in Canada for the treatment of adult patients with RA
- Remsima SC will be the first product to be commercially available in Canada under the new direct sales marketing strategy and is supported by the CELLTRION CONNECT patient support program
- The biosimilar is approved in Canada for use in combination with MTX to reduce the signs and symptoms- inhibit the progression of structural damage and improvement in physical function in adult patients with RA
| Ref: Celltrion | Image: Celltrion
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com